Mengdie Yuan

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Prognostic Factors

Drug Administration

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Sandra J Casak, Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup K Amatya, Joyce Cheng, Pallavi S Mishra-Kalyani, Shenghui Tang, Steven J Lemery, Doris Auth, Gina Davis, Paul G Kluetz, Richard Pazdur, Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Sandra J Casak, Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup K Amatya, Joyce Cheng, Pallavi S Mishra-Kalyani, Shenghui Tang, Steven J Lemery, Doris Auth, Gina Davis, Paul G Kluetz, Richard Pazdur, Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Sandra J Casak, Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup K Amatya, Joyce Cheng, Pallavi S Mishra-Kalyani, Shenghui Tang, Steven J Lemery, Doris Auth, Gina Davis, Paul G Kluetz, Richard Pazdur, Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Sandra J Casak, Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup K Amatya, Joyce Cheng, Pallavi S Mishra-Kalyani, Shenghui Tang, Steven J Lemery, Doris Auth, Gina Davis, Paul G Kluetz, Richard Pazdur, Lola A Fashoyin-Aje
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Sandra J Casak, M Naomi Horiba, Mengdie Yuan, Joyce Cheng, Steven J Lemery, Yuan Li Shen, Wentao Fu, Jason N Moore, Yangbing Li, Youwei Bi, Doris Auth, Nataliya Fesenko, Paul G Kluetz, Richard Pazdur, Lola A Fashoyin-Aje
FDA Approval Summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2 positive RAS wild type colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)